Analysed COGNITION THERAPEUTICS INC (CGTX:NASDAQ) News Sources
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
14-05-2026
yahoo.com
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
21-05-2026
yahoo.com
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?
02-06-2026
yahoo.com
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
16-06-2026
yahoo.com
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
24-06-2026
yahoo.com
Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX)
24-06-2026
advfn.com
Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33%
24-06-2026
stocktwits.com
What is the current price of COGNITION THERAPEUTICS INC (CGTX:NASDAQ)?
The current price of COGNITION THERAPEUTICS INC (CGTX:NASDAQ) is $0.9235.
COGNITION THERAPEUTICS INC (CGTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of COGNITION THERAPEUTICS INC (CGTX:NASDAQ) since the previous trading day is $-0.0259.
COGNITION THERAPEUTICS INC (CGTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of COGNITION THERAPEUTICS INC (CGTX:NASDAQ) since the previous trading day is -2.728%.
What is the most recent average sentiment score for COGNITION THERAPEUTICS INC (CGTX:NASDAQ)?
The most recent average sentiment score for COGNITION THERAPEUTICS INC (CGTX:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for COGNITION THERAPEUTICS INC (CGTX:NASDAQ)?
The most recent sentiment for COGNITION THERAPEUTICS INC (CGTX:NASDAQ) is .
SEC-8K** Filing Available For COGNITION THERAPEUTICS INC (CGTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.